Anti-interleukin-6 monoclonal antibody for cytokine storm in COVID-19

Novel coronavirus disease 2019 (COVID-19) is known to cause severe pneumonia and acute respiratory distress syndrome which may lead to death. Several treatments have been tested in the race to find a treatment regimen for this deadly viral infection. Tocilizumab, a recombinant humanized anti-interle...

Descripción completa

Detalles Bibliográficos
Autores principales: Douedi, Steven, Chaudhri, Moiuz, Miskoff, Jeffrey
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7423207/
https://www.ncbi.nlm.nih.gov/pubmed/32831940
http://dx.doi.org/10.4103/atm.ATM_286_20
Descripción
Sumario:Novel coronavirus disease 2019 (COVID-19) is known to cause severe pneumonia and acute respiratory distress syndrome which may lead to death. Several treatments have been tested in the race to find a treatment regimen for this deadly viral infection. Tocilizumab, a recombinant humanized anti-interleukin-6 receptor monoclonal antibody, has been used and found to be beneficial in patients with COVID-19 and in cytokine storm. We present the case of a young, otherwise healthy male, presenting with COVID-19 and successfully treated in the intensive care unit with tocilizumab.

Ejemplares similares